Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings
On track for full data read out in the first half of 2026
You might also be interested in reading Tether Bets on Bitcoin L2: USDT Eyes RGB and Taproot, Retires Five Chains.